ArticleScientific reports2025
Association between lifetime co-use of classic psychedelics and cannabis and prostate cancer diagnosis among US adults 50 years and older.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Prostate cancer is the second leading cause of cancer-related deaths among U.S. men. While cannabis and classic psychedelics gain attention for symptom management in oncology, their associations with prostate cancer remain unexplored. This study evaluates associations between lifetime classic psychedelic and cannabis use with prostate cancer diagnoses among older U.S. adults using 2015-2019 National Survey on Drug Use and Health (NSDUH) data. A nationally representative sample of 19,460 males (weighted N = 50,842,517) aged ≥ 50 years was included in the analysis. Participants were categorized as: cannabis-only users, classic psychedelic-only users, co-users, and non-users. The primary outcome was self-report of physician-diagnosed prostate cancer. Multivariable logistic regression models estimated the adjusted odds ratios (AORs) for lifetime use and prostate cancer, adjusting for socio-demographic, behavioral, and clinical covariates, and analyses further stratified by age. Among participants, 3.9% reported prostate cancer. Exclusive classic psychedelic use was associated with increased odds of prostate cancer (AOR: 2.62, 95% CI: 1.31-5.22, p < 0.01) versus non-users. Among those ≥ 65, classic psychedelic-only use was also associated with higher odds (AOR: 3.60, 95% CI: 1.71-7.55, p < 0.01) of prostate cancer than non-users. Classic psychedelic-only users had higher odds of prostate cancer versus co-users (AOR: 4.58, 95% CI: 1.89-11.1, p < 0.01). This study identified a novel association between classic psychedelic use and prostate cancer in older adults. Future research should explore reasons for use, potential biological mechanisms, and consider longitudinal studies to clarify causality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.